Pfizer gains priority review for Talzenna/Xtandi combo in prostate cancer
Seeking Alpha ·
The FDA has granted priority review to Pfizer's ( PFE ) sNDA for Talzenna ( talazoparib) in combination with Xtandi (enzalutamide) for metastatic prostate cancer. Although the combo is currently indicated for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), the
DYAX Investor Sentiment
Bullish (Long) 42% · Bearish (Short) 58%
260 participants
Related News
- Leslie's sinks on the report it's considering Chapter 11 bankruptcy
- Intel's Foundry Just Landed Its First Named Outside Customer Under Lip-Bu Tan. The Stock Jumped More Than 8% -- 2 Days Before Earnings.
- BankUnited signals 5%-6% 2026 net interest income growth while lifting NIDDA outlook to 12%-13%
- Stock Market Today, July 22: Nasdaq Slides Prior to Tesla and Alphabet's Earnings After Market Close
- Alphabet Q2 Earnings Call Highlights
- Here are the major earnings before the open Thursday
